Mesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19

Mesoblast (NASDAQ:MESO) slumps 32% after-hours after an update on remestemcel-L trial in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19.
Data Safety Monitoring Board (DSMB) performed a third interim analysis on the trial’s first 180 patients.